Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Short term Debt (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Short term Debt for 11 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short term Debt fell 43.04% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Sep 2025, down 43.04%, and an annual FY2024 reading of $2.5 million, down 3.71% over the prior year.
  • Short term Debt was $2.0 million for Q3 2025 at BioRestorative Therapies, down from $2.6 million in the prior quarter.
  • Across five years, Short term Debt topped out at $14.2 million in Q1 2022 and bottomed at $14687.0 in Q1 2021.
  • Average Short term Debt over 5 years is $4.0 million, with a median of $2.8 million recorded in 2024.
  • The sharpest move saw Short term Debt plummeted 99.66% in 2021, then surged 96621.03% in 2022.
  • Year by year, Short term Debt stood at $58970.0 in 2021, then skyrocketed by 9297.55% to $5.5 million in 2022, then plummeted by 52.76% to $2.6 million in 2023, then fell by 3.71% to $2.5 million in 2024, then fell by 21.92% to $2.0 million in 2025.
  • Business Quant data shows Short term Debt for BRTX at $2.0 million in Q3 2025, $2.6 million in Q2 2025, and $3.2 million in Q1 2025.